I asked Dixon multiple questions. When I asked why Baldwin's resignation was kept quiet he said that his company secretary advised him that new listing rules prevent them from publishing director resignations to market and that they should be kept in quarterly and half annual reports. That is not true at all. Director resignations and appointments should be made to the ASX as they happen.
Dixon wouldn't tell me if he was there for the Astellas deal, or even give me a rough date of his departure. In the 4C it said he was handing over the reigns to the new guy, but it sounded like he was actually long gone from what I picked up. So I gently asked why he left and Dixon kindve danced around the question. Yet in the 4C he wrote that he left to progress his career. If that was really the case why didn't Dixon repeat that on the phone call. Why isn't Baldwin's LinkedIn revealing his hot new company seeing as he found something newer than exosomes.
I asked why a webinar wasn't held and that one should be held to clear up the confusion and he just told me they are going to improve shareholder communication going forward and to talk to Rudi the comms guy in the meantime. That's not like exopharm in the past who would happily answer all and any questions over a zoom meeting every few months.
I sold my shares because I was amazed at how unconfident Ian Dixon sounded on the call along with the low quality answers I got. When I prodded him with questions he was like a little boy who had stolen candy from a store and was about to be discovered by his parents. There was something not quite right and very odd about the whole call. Long, dwindling, dancing around answers to very short simple questions.
He reminds me of the BUD ceo.
We all know how that stock went.
EX1 Price at posting:
32.5¢ Sentiment: Sell Disclosure: Not Held
